Idorsia conducts clinical trials globally to advance its studies. Our key assets have the potential to transform treatment in the target indications.
Currently, we support Idorsia activities and clinical studies out of the following locations:
Our locations
Idorsia Pharmaceuticals Ltd
Headquarters of Idorsia Ltd. Responsible for drug discovery, development, registration, production, quality assurance, safety, as well as company management and coordination.
Idorsia Pharmaceuticals US Inc.
Based in Radnor, Pennsylvania, US – is responsible for the commercial operations in the US.
Idorsia Pharmaceuticals Japan Ltd
Based in Tokyo, Japan – performs clinical development and commercial activities on behalf of Idorsia.
Idorsia Pharmaceuticals Deutschland GmbH
A 100% subsidiary of Idorsia Ltd, based in Lörrach, Germany – performs clinical development on behalf of the Group and acts as the Group’s representative for obtaining regulatory approvals in the EU.
Idorsia Pharmaceuticals Germany GmbH
A 100% subsidiary of Idorsia Ltd, based in Munich, Germany – is responsible for the Group’s marketing operations in Germany.
Idorsia Pharmaceuticals France SAS
A 100% subsidiary of Idorsia Ltd, based in Paris, France – will be responsible for the Group’s marketing operations in France.
Idorsia Pharmaceuticals UK Ltd
A 100% subsidiary of Idorsia Ltd, based in London, United Kingdom – is responsible for the Group’s marketing operations in the United Kingdom.
Idorsia Pharmaceuticals Italy S.R.L.
A 100% subsidiary of Idorsia Ltd, based in Milan, Italy – is responsible for the Group’s marketing operations in Italy.
Idorsia Pharmaceuticals Spain S.L.
A 100% subsidiary of Idorsia Ltd, based in Madrid, Spain – is responsible for the Group’s marketing in Spain.
Idorsia Clinical Development US Inc.
Based in New Jersey, US – performs clinical development on behalf of Idorsia.
Idorsia (Shanghai) Pharmaceuticals Co., Ltd
Based in Shanghai, PRC – performs research and development on behalf of Idorsia.
Idorsia (Beijing) Pharmaceuticals Co., Ltd
Based in Beijing, PRC – performs clinical development on behalf of Idorsia.
Vaxxilon Deutschland GmbH
A 100% subsidiary of Idorsia Ltd, based in Berlin, Germany – discovers and develops synthetic carbohydrate vaccines to prevent infection.